Jeff Yass’s Decoy Therapeutics DCOY Stock Holding History

Jeff Yass’s Portfolio DCOY Stock Details DCOY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Hold	0	–	-$183K	–	10100
2016 Q3	–	Hold	0	–	–	–	7644

Other funds holding DCOY

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jeff Yass's DCOY Position: Q1 2024 in Review

Jeff Yass sold out of Decoy Therapeutics (DCOY) in Q1 2024, closing a stake of 21 shares — an estimated $19.5K sold.

Jeff Yass first reported a position in DCOY in Q4 2020 and held it in 4 quarters. The position peaked at $30K in Q4 2020. 7 funds tracked by Wall St. Rank hold DCOY as of Q1 2024.

Jeff Yass reported no remaining Decoy Therapeutics position as of Q1 2024 after selling out during the quarter.
Jeff Yass sold 21 Decoy Therapeutics shares in Q1 2024, an estimated $19.5K.
Jeff Yass first reported a position in Decoy Therapeutics in Q4 2020 and held it in 4 quarters.
Jeff Yass's Decoy Therapeutics position peaked at $30K in Q4 2020.
7 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.